FluoSphera

FluoSphera is a Swiss biotechnology and pharmaceutical startup, established in 2021, offering groundbreaking in vitro drug discovery solutions. The company's slogan, "The only company with a suite of systemic and high-throughput in vitro drug discovery solutions," underlines its unique value proposition. FluoSphera's proprietary chip-free platform utilizes flexible 3D cell systems to mimic the complex biology of the human body, enabling rapid and precise study of human response to systemic drug delivery. The startup's offerings encompass multiplexing for target selectivity, measuring systemic efficacy and toxicity, systemic biomarker identification, and translational species optimization. Notably, FluoSphera secured an impressive Fr.100.00K debt financing investment on 16 May 2023 from FONGIT Innovation Fund, highlighting investor confidence in the company's innovative approach to drug discovery. The startup's ability to attract investment signifies its potential for growth and impact within the biotechnology and pharmaceutical industries. With its cutting-edge technology and focus on addressing critical challenges in drug development, FluoSphera stands poised to make significant contributions to advancing healthcare and medical research.